08:00 , Nov 10, 2014 |  BC Week In Review  |  Financial News

Sentinext Therapeutics completes venture financing

Sentinext Therapeutics Sdn Bhd , Penang, Malaysia   Business: Infectious   Date completed: 2014-11-06   Type: Venture financing   Raised: $14 million   Investors: Malaysia Venture Capital; Agensi Inovasi Malaysia; Malaysian Life Sciences Capital Fund;...
07:00 , Sep 2, 2013 |  BioCentury  |  Finance

Diagnostic Domain

Diagnostic Domain While diagnostics are becoming a no-fly zone for many VCs, Domain Associates continues to place bets in the space. The firm participated in a $28 million series C round for Applied Proteomics Inc....
07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

Biocon, Manipal Education Malaysia other news

Manipal and Biocon's Biocon Sdn Bhd subsidiary signed a memorandum of understanding to create an internship and graduate employment program for specialized training of graduates of Manipal International University at Biocon's manufacturing and R&D facility...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

First Pharmaceutical, Daiichi Sankyo, Ranbaxy sales and marketing update

Ranbaxy received rights to market Daiichi's antibacterial agent oral Cravit levofloxacin in Malaysia. First Pharmaceutical, which already markets the antibiotic in the country, will transfer marketing rights to Ranbaxy. First Pharma will continue to market...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Financial News

WaferGen completes private placement of convertible preferred stock

WaferGen Biosystems Inc. (OTCBB:WGBS), Fremont, Calif.   Business: Supply/Service   Date completed: 12/15/10   Type: Private placement of convertible preferred stock   Raised: $5 million   Shares: 3.2 million   Price: $1.55   Investor: Malaysian...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Company News

Biocon biosimilars, biomanufacturing news

Biocon plans to invest about RM500 million ($161 million) to establish a biomanufacturing and R&D facility in Malaysian biotech park Bio-XCell. The investment will be made to the Malaysian Biotechnology Corp. Sdn Bhd, the lead...
00:09 , Oct 28, 2010 |  BC Extra  |  Financial News

Biocon to invest $161M in Malaysian biotech

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) plans to invest about RM500 million ($161 million) to establish a biomanufacturing and R&D facility in Malaysian biotech park Bio-XCell. The investment will be made to the Malaysian Biotechnology Corp. Sdn...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Company News

Cevec, Inno Bio Ventures Sdn Bhd deal

Inno Biologics Sdn Bhd, a subsidiary of Inno Bio Ventures, received non-exclusive, worldwide rights to Cevec's CAP expression technology to produce glycosylated human proteins in serum-free cultures. Cevec will receive an undisclosed upfront payment and...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

Grampian Bioconsultants Ltd., Siogen Biotech Sdn Bhd deal

The companies will test the feasibility of combining Grampian's undisclosed antibodies with Siogen's Targeted Designer Siosome drug delivery technology, which encapsulates antibodies and peptides in silicon analogs of organics (silanes). Siogen initially will contribute £20...
08:00 , Nov 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Renal cancer Folliculin (FLCN; BHD); mammalian target of rapamycin (mTOR; FRAP; RAFT1) Studies in mice suggest that mTOR inhibitors could help treat Birt-Hogg-Dube syndrome, an...